During the last session, Mustang Bio Inc. (NASDAQ:MBIO)’s traded shares were 1.44 million, with the beta value of the company hitting 1.69. At the end of the trading day, the stock’s price was $0.69, reflecting an intraday gain of 14.56% or $0.09. The 52-week high for the MBIO share is $3.09, that puts it down -347.83 from that peak though still a striking 26.09% gain since the share price plummeted to a 52-week low of $0.51. The company’s market capitalization is $81.07M, and the average intraday trading volume over the past 10 days was 1.1 million shares, and the average trade volume was 1.04 million shares over the past three months.
Mustang Bio Inc. (MBIO) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.60. MBIO has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.21.
Mustang Bio Inc. (NASDAQ:MBIO) trade information
Mustang Bio Inc. (MBIO) registered a 14.56% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 14.56% in intraday trading to $0.69 this Wednesday, 08/03/22, hitting a weekly high. The stock’s 5-day price performance is 4.15%, and it has moved by 19.54% in 30 days. Based on these gigs, the overall price performance for the year is -74.75%. The short interest in Mustang Bio Inc. (NASDAQ:MBIO) is 0.9 million shares and it means that shorts have 0.64 day(s) to cover.
The consensus price target of analysts on Wall Street is $7.00, which implies an increase of 90.14% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $8.00 respectively. As a result, MBIO is trading at a discount of -1059.42% off the target high and -479.71% off the low.
Mustang Bio Inc. (MBIO) estimates and forecasts
Statistics show that Mustang Bio Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Mustang Bio Inc. (MBIO) shares have gone down -42.07% during the last six months, with a year-to-date growth rate less than the industry average at -11.84% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -31.20% this quarter and then drop -10.50% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -8.50%. While earnings are projected to return 33.80% in 2022.
Mustang Bio Inc. is due to release its next quarterly earnings between March 22 and March 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Mustang Bio Inc. (NASDAQ:MBIO)’s Major holders
Mustang Bio Inc. insiders own 21.03% of total outstanding shares while institutional holders control 25.40%, with the float percentage being 32.17%. Blackrock Inc. is the largest shareholder of the company, while 120 institutions own stock in it. As of Mar 30, 2022, the company held over 5.68 million shares (or 5.56% of all shares), a total value of $5.74 million in shares.
The next largest institutional holding, with 2.98 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 2.92% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $3.01 million.
Also, the Mutual Funds coming in first place with the largest holdings of Mustang Bio Inc. (MBIO) shares are TIAA-CREF Funds-Quant Small Cap Equity Fund and Vanguard Extended Market Index Fund. Data provided on Apr 29, 2022 indicates that TIAA-CREF Funds-Quant Small Cap Equity Fund owns about 1.19 million shares. This amounts to just over 1.17 percent of the company’s overall shares, with a $0.89 million market value. The same data shows that the other fund manager holds slightly less at 1.07 million, or about 1.05% of the stock, which is worth about $1.08 million.